XT
PTGX icon

XTX Topco’s Protagonist Therapeutics PTGX Stock Holding History

XTX Topco’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,260
Closed -$482K – 3696
2025
Q3 		$482K Sell
7,260
-72
-1% -$4.09K 0.03% 1100
2025
Q2 		$405K Sell
7,332
-6,925
-49% -$332K 0.02% 1245
2025
Q1 		$689K Buy
14,257
+7,513
+111% +$315K 0.04% 790
2024
Q4 		$260K Sell
6,744
-8,057
-54% -$351K 0.02% 1338
2024
Q3 		$666K Buy
+14,801
New +$598K 0.05% 628
2023
Q4 		– Sell
-16,139
Closed -$269K – 2022
2023
Q3 		$269K Buy
+16,139
New +$313K 0.05% 807
2023
Q1 		– Sell
-12,942
Closed -$141K – 1587
2022
Q4 		$141K Sell
12,942
-25,882
-67% -$218K 0.03% 938
2022
Q3 		$327K Buy
38,824
+26,201
+208% +$248K 0.08% 459
2022
Q2 		$100K Buy
+12,623
New +$153K 0.04% 645

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

XTX Topco's PTGX Position: Q4 2025 in Review

XTX Topco sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 7,260 shares — an estimated $482K sold.

XTX Topco first reported a position in PTGX in Q2 2022 and held it in 9 quarters. The position peaked at $689K in Q1 2025. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • XTX Topco reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 7,260 Protagonist Therapeutics shares in Q4 2025, an estimated $482K.
  • XTX Topco first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 9 quarters.
  • XTX Topco's Protagonist Therapeutics position peaked at $689K in Q1 2025.
  • 313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.